A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
- 1.5k Downloads
The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at the time of the primary analysis.
Between 30 January 2006 and 29 January 2008, 426 patients with mCRC who failed in first-line chemotherapy were randomly assigned to receive either FOLFIRI or IRIS. After the primary analysis, the follow-up survey was cut off on 29 July 2010, and the final OS data were analysed.
With a median follow-up of 39.2 months, the median OS was 17.4 months in the FOLFIRI group and 17.8 months in the IRIS group [hazard ratio (HR) 0.900; 95 % confidence interval (CI) 0.728–1.112]. In the pre-planned subgroup of patients who received prior chemotherapy containing oxaliplatin, the median OS was 12.7 months in the FOLFIRI group and 15.3 months in the IRIS group (HR 0.755; 95 % CI 0.580–0.983).
IRIS is non-inferior to FOLFIRI for OS as second-line chemotherapy for mCRC. IRIS can be an option for second-line chemotherapy of mCRC. (ClinicalTrials.gov Number: NCT00284258).
KeywordsColorectal cancer FIRIS Irinotecan IRIS S-1
We thank all of the patients, their families, and the institutions involved in this study (see “Appendix”). The authors also thank Yuh Sakata, Yasuo Ohashi, and Nobuyuki Yamamoto for the Independent Data Monitoring Committee, and Atsushi Ohtsu, Yasuaki Arai, and Junji Tanaka for the Independent Central Review Committee for their contributions to this report. The authors dedicate this article to the memory of Prof. Hiroya Takiuchi, who contributed to the conception and design of this study. The senior academic authors designed the trial in cooperation with the study sponsors. The sponsors provided funding and organisational support, collected data, and performed analyses, but did not undertake any data interpretation. This report was written by the corresponding author (with additional input from the other authors), who had unrestricted access to the raw study data, gives assurance for the accuracy and completeness of the reported analyses, and had final responsibility for the decision to submit for publication. This work was funded by Taiho Pharmaceutical Co. Ltd., Japan, and Daiichi Sankyo Co. Ltd., Japan.
Conflict of interest
The authors declare no conflict of interest.
- Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860PubMedCrossRefGoogle Scholar
- National Comprehensive Cancer Network (2014a) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 3.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 20 2014
- National Comprehensive Cancer Network (2014b) NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, version 3.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 20 2014